Cargando…
Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance
Integrase Strand Transfer Inhibitors (INSTIs) are currently used as the most effective therapy in the treatment of human immunodeficiency virus (HIV) infections. Raltegravir (RAL) and Elvitegravir (EVG), the first generation of INSTIs used successfully in clinical treatment, are susceptible to the e...
Autores principales: | Richetta, Clémence, Tu, Nhat Quang, Delelis, Olivier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785060/ https://www.ncbi.nlm.nih.gov/pubmed/36560595 http://dx.doi.org/10.3390/v14122591 |
Ejemplares similares
-
Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors
por: Malet, Isabelle, et al.
Publicado: (2017) -
Different Pathways Leading to Integrase Inhibitors Resistance
por: Thierry, Eloïse, et al.
Publicado: (2017) -
HIV drug resistance against strand transfer integrase inhibitors
por: Anstett, Kaitlin, et al.
Publicado: (2017) -
Integrase Strand Transfer Inhibitors in HIV Therapy
por: Mesplède, Thibault, et al.
Publicado: (2013) -
Reply to Das and Berkhout, “How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir”
por: Malet, Isabelle, et al.
Publicado: (2018)